PHILADELPHIA, PA — Vittoria Biotherapeutics will present groundbreaking research on its innovative Senza5™ platform at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA, from December 7 to 10, 2024. The company’s oral and poster presentations will focus on enhancing engineered T cell therapies by targeting the CD5 pathway, a key regulator of T cell functionality.
The Senza5™ platform improves T cell therapy by eliminating CD5-mediated immunosuppression, an approach that boosts T cell activation and efficacy. Using advanced gene editing, the platform enables more robust immune responses against cancer cells. Further bolstering its innovation, the Senza5™ technology features a rapid five-day manufacturing process, which accelerates production and enhances the therapeutic potential of engineered T cells.
“This technology represents a promising step forward for oncology and immunology therapies,” Vittoria Biotherapeutics said in a statement. The platform is designed to create more durable and potent treatments for diseases that currently have limited options.
The oral presentation, to be delivered by Trang Vu, Ph.D., a Research and Development Scientist at Vittoria, will detail findings on CD5 elimination. Titled CD5 Elimination Enhances CART Cell Proliferation Through JAK-STAT Activation, the presentation is scheduled for Sunday, December 8, 2024, at 9:45 AM PT (Abstract Number 500).
Additionally, the poster presentation by Ruchi P. Patel, Ph.D., also a Research and Development Scientist at Vittoria, will explore preclinical models of T cell malignancies using the Senza5™ technology. The poster, titled Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies, will be displayed on Monday, December 9, 2024, from 6:00 to 8:00 PM PT (Abstract Number 4848).
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.